EBR Systems has raised an additional $13 million, bringing its total 2025 funding to nearly $50 million to support commercialization of its WiSE CRT system—the world’s only wireless left ventricular pacing device for heart failure.
The tiny, rice-sized implant delivers leadless cardiac resynchronization therapy and works with existing pacemakers and defibrillators. FDA-approved last month, it is set for limited release in 2025 and full launch in 2026.
Follow MEDWIRE.AI for updates on leadless pacing and heart failure innovation.
